CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F11%3A11007" target="_blank" >RIV/00216208:11110/11:11007 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/11:11007 RIV/00843989:_____/11:00103099
Result on the web
<a href="http://dx.doi.org/10.1016/S1470-2045(11)70235-2" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(11)70235-2</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Original language description
The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young patients with good-prognosis diffuse large-B-cell lymphoma. Extendedfollow-up was needed to establish long-term effects.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Result description